US · SNDX · BIOTECHNOLOGY
Syndax Pharmaceuticals, Inc. (SNDX) intrinsic value and stock valuation
$8.72as of 2026-11-21 · Mkt cap 1.81B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Syndax Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values SNDX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SNDX’s statements →
Syndax Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0.00 | $0.00 | $139.7M |
| Operating income | -$-273.08M | -$-339.67M | -$-229.95M | -$-151.76M | $26.2M |
| Net income | -$-285.42M | -$-318.76M | -$-209.36M | -$-149.34M | $24.9M |
| EPSd | -$-3.29M | -$-3.72M | -$-2.98M | -$-2.46M | $478.9K |
| Operating cash flow | -$-322.98M | -$-274.9M | -$-160.6M | -$-133.68M | $29.1M |
| Capital expenditure | -$-190K | $0.00 | $0.00 | -$-230K | -$-130K |
| Free cash flow | -$-323.17M | -$-274.9M | -$-160.6M | -$-133.9M | $29M |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M |
| Total debt | $346.5M | $345.7M | $1.64M | $1.16M | $21M |
| Net debt | $211.6M | $191.7M | -$-293.76M | -$-73.19M | -$-201M |
| Total equity | $64.6M | $288.1M | $554.2M | $467.5M | $408.4M |
| Cash and short-term investments | $413.7M | $582.9M | $577.6M | $484.4M | $446.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0.00 | $0.00 | $139.7M |
| Cost of revenue | $6.97M | $830K | $0.00 | $0.00 | $0.00 |
| Gross profit | $165.4M | $22.9M | $0.00 | $0.00 | $139.7M |
| Research and development expenses | $258.8M | $241.7M | $163M | $118.5M | $88.3M |
| Selling, general and administrative expenses | $179.7M | $120.9M | $66.9M | $33.3M | $25.2M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $438.5M | $362.5M | $230M | $151.8M | $113.5M |
| Cost and expenses | $445.4M | $363.4M | $230M | $151.8M | $113.5M |
| Interest income | $22.7M | $26.1M | $21.2M | $5.87M | $400K |
| Interest expense | $33.8M | $4.93M | $210K | $3.14M | $1.9M |
| Depreciation and amortization | $10K | $10K | $10K | $30K | $40K |
| Ebitda | -$-251.63M | -$-313.82M | -$-209.14M | -$-146.17M | $26.9M |
| Operating income | -$-273.08M | -$-339.67M | -$-229.95M | -$-151.76M | $26.2M |
| Total other income/expenses, net | -$-12.34M | $20.9M | $20.6M | $2.42M | -$-1.29M |
| Income before tax | -$-285.42M | -$-318.76M | -$-209.36M | -$-149.34M | $24.9M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-285.42M | -$-318.76M | -$-209.36M | -$-149.34M | $24.9M |
| Weighted average shares outstanding | $86.6M | $85.6M | $70.4M | $60.8M | $52.1M |
| Weighted average diluted shares outstanding | $86.6M | $85.6M | $70.4M | $60.8M | $52.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $413.7M | $582.9M | $577.6M | $484.4M | $446.8M |
| Net receivables | $70.3M | $13.9M | $1.23M | $4.06M | $430K |
| Inventory | $32.8M | $370K | $0.00 | $0.00 | $0.00 |
| Total current assets | $528.1M | $603.1M | $580.9M | $489.8M | $448.4M |
| Property, plant and equipment, net | $1.52M | $2.02M | $1.5M | $1.06M | $1.26M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $119.5M | $29.8M | $5.47M | $0.00 |
| Total non-current assets | $1.62M | $121.8M | $32M | $7.45M | $1.26M |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M |
| Accounts payable | $16.6M | $11.6M | $9.96M | $4.35M | $5.67M |
| Short-term debt | $470K | $12.6M | $1.05M | $440K | $360K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $120.1M | $103.6M | $58.1M | $29.1M | $20.7M |
| Long-term debt | $346M | $333.1M | $590K | $720K | $20.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $345M | $333.1M | $590K | $720K | $20.6M |
| Capital lease obligations | $1.52M | $2.06M | $1.64M | $1.16M | $1.07M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-1.51B | -$-1.22B | -$-902.4M | -$-693.04M | -$-543.7M |
| Accumulated other comprehensive income (loss) | $450K | $160K | $220K | -$-810K | $40K |
| Total equity | $64.6M | $288.1M | $554.2M | $467.5M | $408.4M |
| Total investments | $278.8M | $548.4M | $312M | $415.5M | $224.9M |
| Total debt | $346.5M | $345.7M | $1.64M | $1.16M | $21M |
| Net debt | $211.6M | $191.7M | -$-293.76M | -$-73.19M | -$-201M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-285.42M | -$-318.76M | -$-209.36M | -$-149.34M | $24.9M |
| Depreciation and amortization | $10K | $10K | $10K | $30K | $40K |
| Stock-based compensation | $47.5M | $43M | $31M | $16M | $13.3M |
| Change in working capital | -$-79.32M | $13.3M | $31.9M | $1.66M | -$-9.6M |
| Accounts receivable | -$-36.83M | -$-11.24M | $10.7M | -$-3.47M | $0.00 |
| Inventory | -$-32.09M | -$-370K | $0.00 | $3.47M | $0.00 |
| Accounts payable | $4.95M | $1.67M | $5.61M | -$-1.32M | $2.16M |
| Net cash provided by operating activities | -$-322.98M | -$-274.9M | -$-160.6M | -$-133.68M | $29.1M |
| Investments in property, plant and equipment | -$-190K | $0.00 | $0.00 | -$-230K | -$-130K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $230K | $40K |
| Net cash used for investing activities | $290M | -$-219.78M | $117.6M | -$-186.19M | -$-40.87M |
| Common stock issued | $13.7M | $9.71M | $258.1M | $181.4M | $86.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $13.7M | $353.4M | $264.1M | $172.3M | $118.5M |
| Net change in cash | -$-19.27M | -$-141.31M | $221.1M | -$-147.61M | $106.7M |
| Cash at end of period | $135M | $154.3M | $295.6M | $74.5M | $222.1M |
| Operating cash flow | -$-322.98M | -$-274.9M | -$-160.6M | -$-133.68M | $29.1M |
| Capital expenditure | -$-190K | $0.00 | $0.00 | -$-230K | -$-130K |
| Free cash flow | -$-323.17M | -$-274.9M | -$-160.6M | -$-133.9M | $29M |
Line items
Line items
Line items
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
- CEO
- Michael A. Metzger
- Employees
- 298
- Beta
- 0.37
Explore
Frequently asked questions
What is the intrinsic value of Syndax Pharmaceuticals, Inc. (SNDX)?
Syndax Pharmaceuticals, Inc. (SNDX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SNDX undervalued?
SNDX trades at a price of $8.72 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.